Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Veradermics, Incorporated

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. More about the company

$138.49
+1.29% today
$5.8B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is MANE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2026-02-04 → 2026-10-22
S? 37w
2026-02-042026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 37w current
Total tracked: 37 weeks across 1 stage run.

MANE among Biotechnology565th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…565MANE——+19.6%
vs 52W High
—
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 37
1w13w26w
Week 37, mature
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
—
—
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
1.01x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+19.6%
3M
+26.5%
6M
+100.0%
YTD
—
1Y
—
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-10-22S—
Wk 37 · Vol 1.01x
2026-10-21S—
Wk 36 · Vol 0.90x
2026-10-20S—
Wk 36 · Vol 1.38x
2026-10-19S—
Wk 36 · Vol 1.94x
2026-10-16S—
Wk 36 · Vol 0.90x
2026-10-15S—
Wk 36 · Vol 0.91x
2026-10-14S—
Wk 35 · Vol 0.62x
2026-10-13S—
Wk 35 · Vol 1.03x
2026-10-12S—
Wk 35 · Vol 1.21x
2026-10-09S—
Wk 35 · Vol 1.38x
2026-10-08S—
Wk 35 · Vol 4.66x
2026-10-07S—
Wk 34 · Vol 0.87x
Moving averages & range
50 DMA
$110.89
200 DMA
—
52W High
—
52W Low
—
5D Low
$108.82
Resistance levels (recent highs)
20d High
$138.49
60d High
$138.49
120d High
$138.49
250d High
—
Next resistance
Above all
Dividend Yield
0.00%
P/B 7.1

Veradermics: quick answers

Which sector and industry is Veradermics in?

Veradermics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.